TVRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tvardi Therapeutics Inc (TVRD) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. While there is some potential for future developments, the current data does not justify an immediate investment.
The MACD is positive and expanding, indicating a mild bullish momentum. However, the RSI is neutral at 53.636, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 3.105, with resistance at 3.391 and support at 2.819. Overall, the technical indicators do not strongly support a buy decision.
The stock is trading near its cash value levels, which might provide some downside protection.
Both Piper Sandler and Barclays lowered their price targets to $3 and $4, respectively, reflecting cautious sentiment. The company's financial performance is weak, with a significant drop in net income (-42.75% YoY) and EPS (-84.41% YoY). No recent news or significant insider/hedge fund activity has been reported.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$7.275 million (-42.75% YoY), and a sharp decline in EPS to -0.77 (-84.41% YoY). Gross margin remains at 0%. Overall, the financials indicate poor performance and no growth trends.
Analyst sentiment is mixed to negative. Piper Sandler and Barclays lowered their price targets, maintaining Neutral and Equal Weight ratings, respectively. Lucid Capital upgraded the stock to Buy with a $6 price target, citing undervaluation and potential catalysts in TTI-101 and TTI-109.
